In recent years, Immune Checkpoint Inhibitors (ICIs) anti-PD-1 (programmed death 1) or anti-PD-L1 (programmed death-ligand 1) antibodies, have shown promising results in clinical trials and are approved for the treatment of advanced NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.